RASUVO®, an antineoplastic medication that impedes dihydrofolate reductase (DHFR), has gained notoriety since its approval by the US in 1953. Its multifarious applications include treatment for acute lymphoblastic leukemia, breast cancer, severe psoriasis, rheumatoid arthritis, and juvenile rheumatoid arthritis. Indeed, Methotrexate's versatility in managing such afflictions has made it a vital resource in the medical field, elevating patient outcomes and reducing the burden of debilitating illnesses. Pfizer Inc., the pharmaceutical company responsible for its development, has achieved a remarkable feat in crafting such a compound that serves such a wide array of purposes. Through the ages, Methotrexate has proven its efficacy and usefulness, paving the way for a brighter future in the realm of modern medicine. Click on the image below to begin the exploration journey of Methotrexate through the Synapse database!
You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!